Trial reportNature communications2026
Safety and immunogenicity of inactivated human Rotavirus vaccine in young children and infants: a randomized, placebo-controlled, double-blind, phase I clinical trial.
Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04626856 (Evaluation of the Safety and Preliminary Immunogenicity of Inactivated Rotavirus Vaccine), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Safety and Preliminary Immunogenicity of Inactivated Rotavirus Vaccine (Vero Cell) in Healthy Population: a Randomized, Double-blind, Placebo Parallel-controlled Phase I Clinical Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inactivated rotavirus vaccines (IRV) are an effective approach for providing protection against the virus. This double-blind, randomised, placebo-controlled, dose-escalation phase I trial evaluated the safety and immunogenicity of IRV in 288 healthy children aged 2-71 months without prior rotavirus vaccination or HIV infection. We stratified participants by age (7-71 months and 2-6 months) and schedule (2 or 3 doses), before randomising them 3:1 to receive one of three antigen doses (80, 160, or 320 ELISA Unit [EU]), or aluminium adjuvanted placebo. The primary endpoints included adverse reactions/events within 30 min post-dose, adverse reactions/events during days 0-7 and 8-28/30 post-dose, and serious adverse events (SAEs) 6 months after the full course. The secondary endpoints were neutralizing antibody (NTA) geometric mean titres (GMT) and seroconversion rates (≥4-fold rise) at day 28 post-final dose. IRV was well tolerated, with no vaccine-related SAEs in any of the cohorts; we observed clinically manageable transient mild-to-moderate fever in the high dose infant group. Dose-dependent increases in NTA and IgG antibody responses were observed across all cohorts. In the 3-dose infant group, the 320 EU dose yielded a GMT of 551.98 (95% CI 338.39 ~ 900.40) compared to 36.17 for placebo, and a seroconversion rate of 83.33% (vs. 10.00% for placebo); the 3-dose schedule outperformed the 2-dose regimen. Our findings confirm that IRV has a favourable safety and immunogenicity profile. This trial is registered with ClinicalTrials.gov (NCT04626856).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.